 |
      
|
|
|
|
|
|||||
|
|
September 13, 2005
Neurochem announces launch of European Phase III clinical trial on Alzhemed™ for treatment of
Alzheimer's Disease About Alzhemed™
Azhemed™ is an orally administered, small organic molecule specifically designed to modify the course of AD
by binding to soluble amyloid ß (Aß) protein and keeping it in a non-fibrillar form. As reported previously, results
of the Phase II trial demonstrated that there were no apparent safety findings of concern in patients treated with
Alzhemed™ and that the investigational product candidate was well tolerated in individuals with mild-to-moderate
AD. About Alzheimer's Disease
Alzheimer's Disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a
person's cognitive and motor functions and gradually destroys the brain. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug and a Fast Track Product candidate and
is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was recently concluded. The Company is in the process of submitting
a New Drug Application (NDA) for Fibrillex™ that the FDA has agreed to file and review. 3-amino-1-propanesulfonic
acid (3APS; Alzhemed™), for the treatment of Alzheimer's disease, is in a Phase III clinical trial and 3APS
(Cerebril™), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a
Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem Inc.'s control. The risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in
which Neurochem Inc. does business, stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation, as well as other risks disclosed in public filings of Neurochem Inc. Consequently,
actual future results may differ materially from the anticipated results expressed in the forward-looking statements.
The reader should not place undue reliance on, if any, the forward-looking statements included in this news release.
These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention
to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual
Information Form for further risk factors that might affect the Company and its business.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
